Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06026410 | KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors(FIT-001) | recruiting | Phase 1 | 300 | Kura Oncology, Inc.INDUSTRY | 5 | Jun 8, 2026 | clinicaltrials |
| NCT04297605 | Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 | recruiting | Phase 1 | 60 | University of RochesterOTHER | 1 | Jun 4, 2026 |
| clinicaltrials |
| NCT05751798 | Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas | recruiting | Phase 1 / Phase 2 | 41 | OSE ImmunotherapeuticsINDUSTRY | 3 | Jun 4, 2026 | clinicaltrials |
| NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | recruiting | Phase 1 | 150 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | recruiting | Phase 1 | 604 | Revolution Medicines, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT06917079 | BBO-11818 in Adult Subjects With KRAS Mutant Cancer | recruiting | Phase 1 | 665 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT07454642 | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors(FOCUS-01) | recruiting | Phase 1 | 174 | Avacta Life Sciences LtdINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06566443 | Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer | recruiting | Phase 1 | 15 | The Methodist Hospital Research InstituteOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT06868849 | A Study of JMT203 in Patients With Cancer Cachexia | recruiting | Phase 1 / Phase 2 | 307 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT05431270 | Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | recruiting | Phase 1 / Phase 2 | 40 | Phanes TherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07594522 | A Study of Ivonescimab in People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07332858 | First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion | recruiting | Phase 1 / Phase 2 | 105 | Gang HouOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04789486 | Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06922591 | Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | recruiting | Phase 1 / Phase 2 | 183 | Tango Therapeutics, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT05492682 | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | recruiting | Phase 1 | 15 | Valo Therapeutics OyINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT07561723 | IMP3-saRNA Vaccine in Advanced NSCLC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06195189 | Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II(WU-KONG36) | recruiting | Phase 1 / Phase 2 | 40 | Sichuan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06431685 | Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer | recruiting | Phase 1 | 10 | Sichuan UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06800339 | A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer(NEORADJUVANT) | recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06217757 | Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC | recruiting | Phase 1 / Phase 2 | 45 | Sichuan UniversityOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07563738 | A 2-part Phase 1/2 Open-label Trial on ODM-212(TEADCO) | recruiting | Phase 1 / Phase 2 | 229 | Orion Corporation, Orion PharmaINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07249879 | This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. | recruiting | Phase 1 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07231445 | Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer | recruiting | Phase 1 | 100 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 140 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT05482568 | A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 324 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT07535463 | A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 53 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05713006 | Alectinib Pharmacokinetic in Patients With NSCLC | recruiting | Phase 1 / Phase 2 | 45 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT05987644 | Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements(DURABLE) | recruiting | Phase 1 / Phase 2 | 56 | Joshua PalmerOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 386 | Conjupro Biotherapeutics, Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05752552 | Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours | recruiting | Phase 1 | 55 | DeuterOncologyINDUSTRY | 3 | Apr 3, 2026 | clinicaltrials |
| NCT06249282 | Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07354061 | Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)(TD-ENSEMBLE) | recruiting | Phase 1 / Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04762199 | MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer | recruiting | Phase 1 | 69 | Emory UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05254184 | KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC | recruiting | Phase 1 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06868732 | Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | recruiting | Phase 1 | 288 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials